Picornavirus-initiated inflamation: novel parallels from Drosophila

小核糖核酸病毒引发的炎症:果蝇的新相似之处

基本信息

项目摘要

DESCRIPTION (provided by applicant): Virus infections are recognized as a major cause of myocarditis (or inflammation of the heart muscle), and chronic myocarditis often leads to more severe cardiac disease (including dilated cardiomyopathy) that accounts for approximately half of all heart transplant cases. In particular, picornaviruses such as type B coxsackieviruses are considered the prototypic causative agents of viral myocarditis. While the link between picornavirus infections and viral myocarditis has been well-established, little is known about the molecular mechanisms by which a picornavirus infection of the cardiomyocyte initiates inflammation. Cardiomyocytes detect the presence of a picornavirus in the cytoplasm via RNA helicases called RLRs (RIG-I-like receptors). The primary objective of this proposal is to determine how RLRs activate NF-?B to trigger inflammatory responses following picornavirus infection. Identifying the mechanisms by which the NF-?B-regulated pro-inflammatory signal is generated will inform rational therapeutic strategies to alter the balance between a beneficial antiviral response and a deleterious myocardial inflammatory reaction. We propose that picronaviruses activate RLRs to trigger formation of a novel cytoplasmic signaling complex that we call the FADDosome. Our previous work has shown that the FADDosome (comprising the molecules FADD, TRADD, RIP1 and select caspases) specifically activates NF-?B following virus infection, but the mechanism by which the FADDosome regulates NF-?B is unknown. FADD-based NF-?B activation appears to be unique in vertebrate biology, but shares strong parallels with an under-appreciated innate immune pathway in Drosophila called Immune Deficient (IMD). Based on these provocative similarities, we hypothesize that a Drosophila IMD-like signaling module is conserved in vertebrates where it mediates NF-?B activation by the FADDosome in response to RLRs. In this proposal, we will (1) draw comparisons from the established IMD pathway to identify how the FADDosome activates NF-?B following stimulation of RLRs by picornaviruses, and (2) test the feasibility of RLR-NF-?B inhibition as a therapeutic avenue for picornavirus-driven myocarditis.
描述(由申请人提供):病毒感染被认为是心肌炎(或心肌炎症)的主要原因,慢性心肌炎通常导致更严重的心脏疾病(包括扩张型心肌病),约占所有心脏移植病例的一半。特别地,小核糖核酸病毒如B型柯萨奇病毒被认为是病毒性心肌炎的原型病原体。虽然小核糖核酸病毒感染和病毒性心肌炎之间的联系已经很好地建立,但对心肌细胞的小核糖核酸病毒感染引发炎症的分子机制知之甚少。心肌细胞通过称为RLR(RIG-I样受体)的RNA解旋酶检测细胞质中小核糖核酸病毒的存在。这项建议的主要目标是确定如何RLRs激活NF-?B在小核糖核酸病毒感染后引发炎症反应。确定NF-?B调节的促炎信号的产生将为合理的治疗策略提供信息,以改变有益的抗病毒反应和有害的心肌炎症反应之间的平衡。 我们认为,picronaviruses激活RLR触发形成一种新的细胞质信号复合物,我们称之为FADDosome。我们以前的工作表明,FADDosome(包括分子FADD,TRADD,RIP 1和选择半胱天冬酶)特异性激活NF-?B病毒感染后,但FADDosome调节NF-?B未知。基于FADD的NF-?B激活在脊椎动物生物学中似乎是独特的,但与果蝇中被称为免疫缺陷(IMD)的未被充分认识的先天免疫途径有很强的相似之处。基于这些挑衅的相似性,我们假设果蝇IMD样信号模块是保守的脊椎动物,它介导NF-?FADDosome响应于RLR激活B。在这个提议中,我们将(1)从已建立的IMD途径进行比较,以确定FADDosome如何激活NF-?B,以及(2)测试RLR-NF-?B抑制作为小RNA病毒驱动的心肌炎的治疗途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SIDDHARTH BALACHANDRAN其他文献

SIDDHARTH BALACHANDRAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SIDDHARTH BALACHANDRAN', 18)}}的其他基金

Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy
ZBP1 驱动的核坏死性凋亡的小分子开发用于癌症免疫治疗
  • 批准号:
    10586659
  • 财政年份:
    2023
  • 资助金额:
    $ 26.78万
  • 项目类别:
Harnessing ZBP1-triggered cell death to enhance influenza vaccine responsiveness
利用 ZBP1 触发的细胞死亡来增强流感疫苗的反应性
  • 批准号:
    10884586
  • 财政年份:
    2023
  • 资助金额:
    $ 26.78万
  • 项目类别:
Role of ZBP1 in pathogenesis of Salmonella biofilms
ZBP1 在沙门氏菌生物膜发病机制中的作用
  • 批准号:
    10658383
  • 财政年份:
    2023
  • 资助金额:
    $ 26.78万
  • 项目类别:
Necroptosis in SARS-CoV-2 pathogenesis, evolution, and therapy
SARS-CoV-2 发病机制、进化和治疗中的坏死性凋亡
  • 批准号:
    10557863
  • 财政年份:
    2022
  • 资助金额:
    $ 26.78万
  • 项目类别:
Necroptosis in SARS-CoV-2 pathogenesis, evolution, and therapy
SARS-CoV-2 发病机制、进化和治疗中的坏死性凋亡
  • 批准号:
    10433040
  • 财政年份:
    2022
  • 资助金额:
    $ 26.78万
  • 项目类别:
Harnessing ZBP1-driven cell death to improve influenza vaccine efficacy
利用 ZBP1 驱动的细胞死亡来提高流感疫苗的功效
  • 批准号:
    10455196
  • 财政年份:
    2021
  • 资助金额:
    $ 26.78万
  • 项目类别:
Targeting RIPK3 in Flu-Associated Lung Injury
靶向 RIPK3 治疗流感相关肺损伤
  • 批准号:
    10020307
  • 财政年份:
    2019
  • 资助金额:
    $ 26.78万
  • 项目类别:
Targeting RIPK3 in Flu-Associated Lung Injury
靶向 RIPK3 治疗流感相关肺损伤
  • 批准号:
    10470746
  • 财政年份:
    2019
  • 资助金额:
    $ 26.78万
  • 项目类别:
Targeting RIPK3 in Flu-Associated Lung Injury
靶向 RIPK3 治疗流感相关肺损伤
  • 批准号:
    10689229
  • 财政年份:
    2019
  • 资助金额:
    $ 26.78万
  • 项目类别:
Targeting RIPK3 in Flu-Associated Lung Injury
靶向 RIPK3 治疗流感相关肺损伤
  • 批准号:
    10238084
  • 财政年份:
    2019
  • 资助金额:
    $ 26.78万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.78万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 26.78万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.78万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.78万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.78万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.78万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.78万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 26.78万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 26.78万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 26.78万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了